- Medigene to Present at Upcoming Scientific Conferences
- Medigene Presents Favorable Safety Profile of TCR-T Cells with Costimulatory Switch Protein at AACR Annual Meeting 2024
- Medigene AG Secures European Patent for its iM-TCR Technology
- Medigene AG Reports Full-Year 2023 Financial Results and Provides Corporate Update
- Medigene AG to participate in the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
- Medigene AG to report full year 2023 financial results on March 28, 2024
- Medigene to Present Favorable Safety Profile of TCR-T Cells upon Addition of Costimulatory Switch Protein with a Poster Presentation at AACR 2024 Annual Meeting
- Medigene AG Expands Patent Portfolio in Japan for iM-TCR Technology to Directly Control TCR-T Safety and Efficacy, In Vivo
- Medigene Presents at CAR-TCR Summit Europe Showcasing Unique Approach for Development of Differentiated TCR-T Therapies
- Medigene to Present at Upcoming Conferences
More ▼
Key statistics
On Tuesday, Medigene AG (MDG1X:GER) closed at 1.72, 27.41% above the 52 week low of 1.35 set on Dec 14, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.66 |
---|---|
High | 1.89 |
Low | 1.61 |
Bid | 1.75 |
Offer | 1.80 |
Previous close | 1.92 |
Average volume | 26.70k |
---|---|
Shares outstanding | 24.56m |
Free float | 23.69m |
P/E (TTM) | -- |
Market cap | 47.16m EUR |
EPS (TTM) | -- |
Data delayed at least 15 minutes, as of Apr 23 2024 16:38 BST.
More ▼